Overview: Anti-Phosphatidylserine IgM Antibody Rapid TestIntroduction: The Anti-Phosphatidylserine IgM Antibody Rapid Test is a diagnostic tool designed to detect Anti-Phosphatidylserine IgM antibodies in serum, whole blood, or saliva samples, facilitating the screening of antiphospholipid syndrome (APS). Associated with autoimmune clotting disorders, this condition presents with clotting, miscarriage, and severe complications like stroke if untreated, particularly in women with recurrent pregnancy loss or autoimmune diseases. Per the 2023 American College of Rheumatology guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with reasonable sensitivity and specificity, making it a valuable tool for initial screening in obstetrics or rheumatology clinics. This rapid diagnostic falls under immunology and targets individuals with clotting history or pregnancy complications, addressing the challenge of early detection to guide anticoagulation therapy like heparin. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling early identification, facilitating treatment, and reducing adverse outcomes. Its multi-sample capability enhances its utility.Other Names: Anti-Phosphatidylserine IgM Rapid Test.FDA Status: FDA approved, CLIA certified for immunology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by Inova Diagnostics, this test advanced APS detection, providing a rapid alternative to ELISA with a focus on IgM.Purpose: The test screens for Anti-Phosphatidylserine IgM to guide APS diagnosis, assess clotting risk, and inform treatment and prevention strategies.Test Parameters: Presence of Anti-Phosphatidylserine IgM Antibody, detected with reasonable specificity to indicate autoimmune activity, typically detectable in serum or blood during active disease.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report clotting, miscarriage, or joint pain.Specimen: Serum 2-5 mL, Whole Blood 2-5 mL, Saliva 1-2 mL, collected using sterile SST or EDTA tubes/containers, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve antibody integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may degrade antibodies, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on clotting, miscarriage, lupus, or prior APS diagnosis, as well as any family history of autoimmune diseases or recent infections.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated APS including stroke, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid hemolysis or contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or recent infections can affect results. Correlation with lupus anticoagulant or clinical evaluation is recommended to confirm findings.Clinical Significance: A positive result indicates possible APS, necessitating further investigation like lupus anticoagulant or rheumatology consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled during inactive disease.Specialist Consultation: Rheumatologists or hematologists should be consulted for case management, treatment planning, and coordination with autoimmune disease programs.Additional Supporting Tests: Lupus anticoagulant, anti-cardiolipin, or aPTT for confirmation.Test Limitations: The test may produce false positives in other autoimmune conditions or false negatives in early disease, requiring a comprehensive diagnostic approach that includes clinical correlation.References: ACR Guidelines 2023, Arthritis and Rheumatism 2024, Immunology 2025.